Macquarie Group’s Vaxcyte PCVX Stock Holding History

Macquarie Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-80,000	Closed	-$2.88M	–	1317
2025 Q3	$2.88M	Hold	80,000	–	–	﹤0.01%	1074
2025 Q2	$2.6M	Sell	80,000 -109,793	-58%	-$3.6M	﹤0.01%	1148
2025 Q1	$7.17M	Sell	189,793 -58,241	-23%	-$4.66M	0.01%	888
2024 Q4	$20.3M	Buy	248,034 +39,159	+19%	+$3.89M	0.02%	649
2024 Q3	$23.9M	Buy	208,875 +49,863	+31%	+$4.49M	0.03%	625
2024 Q2	$12M	Buy	+159,012	New	+$10.8M	0.01%	777
2022 Q3	–	Sell	-928	Closed	-$23.5K	–	2172
2022 Q2	$20K	Hold	928	–	–	﹤0.01%	2309
2022 Q1	$22K	Hold	928	–	–	﹤0.01%	2369
2021 Q4	$22K	Sell	928 -1,064	-53%	-$24.7K	﹤0.01%	2375
2021 Q3	$51K	Hold	1,992	–	–	﹤0.01%	2231
2021 Q2	$45K	Buy	+1,992	New	+$40.8K	﹤0.01%	2178

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Macquarie Group's PCVX Position: Q4 2025 in Review

Macquarie Group sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 80,000 shares — an estimated $2.88M sold.

Macquarie Group first reported a position in PCVX in Q2 2021 and held it in 11 quarters. The position peaked at $23.9M in Q3 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Macquarie Group reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 80,000 Vaxcyte shares in Q4 2025, an estimated $2.88M.
Macquarie Group first reported a position in Vaxcyte in Q2 2021 and held it in 11 quarters.
Macquarie Group's Vaxcyte position peaked at $23.9M in Q3 2024.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.